Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denufosol in Rhegmatogenous Retinal Detachment
NCT00083967Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2004
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of denufosol tetrasodium in rhegmatogenous retinal detachment (RRD) (4 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability of single and/or multiple intravitreal injections of denufosol and Efficacy of denufosol vs. placebo as a treatment for detachment of the retina. Started Jun 2004; status: terminated.
02
Drugs
denufosol tetrasodium
03
Conditions
rhegmatogenous retinal detachment (RRD)
Beyond the preview
Go deeper on NCT00083967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083967.